articles
- GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures. 18:59-82. 2019
- Senotherapeutics for healthy ageing. 17. 2018
- New treatment options for hearing loss. 14:346-365. 2015
- Targeting protein aggregation for the treatment of degenerative diseases. 14:759-780. 2015
- Market watch: Upcoming market catalysts in Q2 2014. 13:249-249. 2014
- REV-ERB and ROR nuclear receptors as drug targets. 13:197-216. 2014
- The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. 12:25-34. 2013
- The pharmacological landscape and therapeutic potential of serine hydrolases. 11:52-68. 2012
- Carbohydrate vaccines: Developing sweet solutions to sticky situations?. 9:308-324. 2010
- Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. 8:297-307. 2009
- Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. 8:455-463. 2009
- Development of pharmacotherapies for drug addiction: a Rosetta stone approach. 8:500-515. 2009
- Transient receptor potential channels: Targeting pain at the source. 8:55-68. 2009
- Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. 5:160-170. 2006
- Antibody targeted drugs as cancer therapeutics. 5:147-159. 2006
- The state of GPCR research in 2004. 3:574-626. 2004
- Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. 2:999-1017. 2003
- Scientific and therapeutic advances in antiplatelet therapy. 2:15-28. 2003
- NMR in drug discovery. 1:211-219. 2002
- Therapeutic strategies for human amyloid diseases. 1:267-275. 2002